Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Arrowhead Prices $36 Million Private Offering

Published: Wednesday, May 01, 2013
Last Updated: Wednesday, May 01, 2013
Bookmark and Share
Arrowhead Research Corporation announced that it has priced a private offering with gross proceeds expected to be $36 million. The offering was priced at $1.83 per common share.

Approximately 14.3 million shares of common stock and 9,900 shares of series B convertible preferred stock are expected to be issued at closing. The series B preferred shares are priced at $1,000 per share, are convertible into shares of common stock at a conversion price of $1.83 per share of common stock and include no dividends or liquidation preferences. The offering is expected to close on or about May 3, 2013, subject to the satisfaction of customary closing conditions.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

The securities sold in the private placement have not been registered under the Securities Act of 1933, as amended, or state securities laws and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (SEC) or an applicable exemption from such registration requirements. The Company has agreed to file a registration statement with the SEC registering the resale of the shares of common stock and the shares of common stock issuable upon conversion of the series B preferred.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More Than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Arrowhead Begins Trial of ARC-AAT
The company has announced that it has dosed the first patient in Part B of a Phase 1 clinical trial of ARC-AAT.
Friday, July 03, 2015
Arrowhead Publishes Data on Advances in Subcutaneous siRNA Delivery
The company believes the new Dynamic Polyconjugates are highly potent and may represent a dramatic improvement in duration of activity over competing technologies.
Wednesday, May 06, 2015
Arrowhead Acquires Novartis' RNAi R&D Portfolio
The acquisition includes multiple patent families covering RNAi-trigger design rules and modifications.
Friday, March 06, 2015
Arrowhead Begins Phase 1 Trial of RNAi Therapeutic ARC-520
ARC-520 is the company’s candidate for the treatment of chronic hepatitis B virus infection.
Wednesday, July 24, 2013
Arrowhead to Present at Upcoming Scientific Conferences
Company will present data on the Dynamic PolyConjugate™ (DPC) siRNA delivery system and the ARC-520 hepatitis B drug candidate.
Tuesday, May 14, 2013
Arrowhead Data Demonstrates RNAi Candidate ARC-520 Silences Hepatitis B Virus
Single injection induces multi-log repression of viral RNA, proteins, and viral DNA.
Wednesday, February 27, 2013
Arrowhead Research Corporation Acquires Alvos Therapeutics
Alvos previously licensed a large platform of proprietary human-derived homing peptides from MD Anderson Cancer Center (MDACC) and the method for their discovery.
Thursday, April 12, 2012
Calando Submits IND for Clinical Trial with Targeted, Nano-Delivered RNAi Therapeutic for Cancer
Arrowhead Research Corporation’s subsidiary Calando Pharmaceuticals plans to initiate a Phase I clinical trial using their lead anti-cancer compound.
Wednesday, March 19, 2008
Unidym Licenses Technology to Incorporate Carbon Nanotubes into Miniaturized Medical Devices
Nanotech Catheter Solutions will use Unidym's carbon nanotube technology in the development of medical devices for the treatment of cardiovascular disease.
Tuesday, August 07, 2007
Arrowhead Subsidiary, Insert, Publishes Interim Phase I Data from Human Clinical Trials for new Cancer Drug
The data from a Phase I clinical study of anti-cancer drug candidate has been published in the 2007 American Society for Clinical Oncology Proceedings.
Monday, June 04, 2007
Arrowhead to Fund Stem Cell Research at Caltech
Arrowhead to sponsor the continued research of Dr. Eric Davidson’s laboratory at the California Institute of Technology with $255,000 annually for three years.
Wednesday, January 31, 2007
Arrowhead Raises Additional Capital from Institutional Shareholders
A portion of the proceeds of the sale was used to increase Arrowhead's ownership in RNAi subsidiary.
Monday, August 21, 2006
Arrowhead Announces the Issuance of Patent Covering a New Approach to Targeted Therapeutics
In addition to covering applications pursued by Insert, the technology is licensed for use in RNAi therapeutics to Calando Pharmaceuticals.
Thursday, April 13, 2006
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
New Analysis Technique for Chiral Activity in Molecules
Professor Hyunwoo Kim of the Chemistry Department and his research team have developed a technique that can easily analyze the optical activity of charged compounds by using nuclear magnetic resonance (NMR) spectroscopy.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Best Test to Diagnose Strangles in Horses Identified
New research by Dr. Ashley Boyle of New Bolton Center’s Equine Field Service team shows that the best method for diagnosing Strangles in horses is to take samples from a horse’s guttural pouch and analyze them using a loop-mediated amplification (LAMP) polymerase chain reaction (PCR) test.
Tardigrade's Are DNA Master Thieves
Tardigrades, nearly microscopic animals that can survive the harshest of environments, including outer space, hold the record for the animal that has the most foreign DNA.
Lucentis Effective for Proliferative Diabetic Retinopathy
NIH-funded clinical trial marks first major advance in therapy in 40 years.
Antibiotics on Our Plates 'Could Lead to Health Catastrophe'
Two medical experts from The University of Queensland are urging China to curb its use of antibiotics in animals to avoid what could be a ‘major health catastrophe’ for humans.
The Secret Behind the Power of Bacterial Sex
Migration between different communities of bacteria is the key to the type of gene transfer that can lead to the spread of traits such as antibiotic resistance, according to researchers at Oxford University.
Farming’s in Their DNA
Ancient genomes reveal natural selection in action.
Personalized Drug Screening for Multiple Myeloma Patients
A personalized method for testing the effectiveness of drugs that treat multiple myeloma may predict quickly and more accurately the best treatments for individual patients with the bone marrow cancer.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos